Streetbeat News

Analyst Ratings

MDT

Truist Securities analyst Richard Newitter has maintained a Hold rating on Medtronic (NYSE:MDT) and increased the price target from $84 to $87.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:56 pm

ISRG

Truist Securities analyst Richard Newitter has maintained a Buy rating on Intuitive Surgical (NASDAQ:ISRG) and increased the price target from $375 to $390.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:54 pm

IART

Truist Securities analyst Richard Newitter has maintained a Hold rating on Integra Lifesciences (NASDAQ:IART) and increased the price target from $44 to $46.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:53 pm

INSP

Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Inspire Medical Systems (NYSE:INSP) and increased the price target from $240 to $260. This adjustment suggests a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:51 pm

NARI

Truist Securities analyst Richard Newitter has maintained a Hold rating on Inari Medical (NASDAQ:NARI) and increased the price target from $65 to $70.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:50 pm

GMED

Truist Securities analyst Richard Newitter has maintained a Hold rating on Globus Medical (NYSE:GMED) and increased the price target from $53 to $58.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:49 pm

GKOS

Truist Securities analyst Samuel Brodovsky has maintained a Buy rating on Glaukos Corporation (NYSE:GKOS) and increased the price target from $88 to $100.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:47 pm

EW

Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $78 to $84. This adjustment reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:45 pm

CTAS

Truist Securities analyst Jasper Bibb has reaffirmed a Buy rating on Cintas (NASDAQ:CTAS) and increased the price target from $625 to $645.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:44 pm

CTAS

Truist Securities analyst Jasper Bibb has reaffirmed a Buy rating on Cintas (NASDAQ:CTAS) and increased the price target from $625 to $645.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 2:43 pm